- Home
- LXRX vs DCTH Comparison
LXRX vs DCTH Comparison
Compare LXRX & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXRX
- DCTH
- Stock Information
- Founded
- LXRX 1995
- DCTH 1988
- Country
- LXRX United States
- DCTH United States
- Employees
- LXRX N/A
- DCTH N/A
- Industry
- LXRX Biotechnology: Pharmaceutical Preparations
- DCTH Medical/Dental Instruments
- Sector
- LXRX Health Care
- DCTH Health Care
- Exchange
- LXRX Nasdaq
- DCTH Nasdaq
- Market Cap
- LXRX 428.8M
- DCTH 388.3M
- IPO Year
- LXRX 2000
- DCTH N/A
- Fundamental
- Price
- LXRX $1.13
- DCTH $10.69
- Analyst Decision
- LXRX Buy
- DCTH Strong Buy
- Analyst Count
- LXRX 5
- DCTH 4
- Target Price
- LXRX $3.23
- DCTH $24.50
- AVG Volume (30 Days)
- LXRX 1.8M
- DCTH 486.2K
- Earning Date
- LXRX 11-11-2025
- DCTH 11-07-2025
- Dividend Yield
- LXRX N/A
- DCTH N/A
- EPS Growth
- LXRX N/A
- DCTH N/A
- EPS
- LXRX N/A
- DCTH 0.06
- Revenue
- LXRX $58,432,000.00
- DCTH $70,240,000.00
- Revenue This Year
- LXRX N/A
- DCTH $159.22
- Revenue Next Year
- LXRX N/A
- DCTH $41.22
- P/E Ratio
- LXRX N/A
- DCTH $199.29
- Revenue Growth
- LXRX 1504.83
- DCTH 491.35
- 52 Week Low
- LXRX $0.28
- DCTH $8.08
- 52 Week High
- LXRX $2.18
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- LXRX 50.83
- DCTH 44.22
- Support Level
- LXRX $1.03
- DCTH $11.01
- Resistance Level
- LXRX $1.15
- DCTH $11.93
- Average True Range (ATR)
- LXRX 0.06
- DCTH 0.44
- MACD
- LXRX -0.01
- DCTH 0.04
- Stochastic Oscillator
- LXRX 50.00
- DCTH 6.25
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.